Just back from the ESCGT 2025 in Sevilla Spain with my fantastic post docs who presented their work on engineering AAV producer cell lines and novel ways to address gene dosage compensation in gene replacement therapy, all using #syntheticbiology
#Syntheticbiology to advance gene and cell therapy in rare genetic disease is our major focus. We rely on biomedical engineering, molecular biology and bioinformatics to achieve this goal. dibernardo.tigem.it